.png){kind=small}
.png){kind=small}
BackTable / Urology / Podcast / Episode #290
Urothelial Carcinoma: Consolidative Surgery & Treatment Approaches
with Dr. Abhinav Khanna
What do you do when metastatic urothelial cancer responds dramatically to systemic therapy? In this episode of BackTable Urology, Dr. Abhinav Khanna (Mayo Clinic) speaks with host Dr. Daniel Roberson about the growing question of consolidative surgery after enfortumab vedotin plus pembrolizumab. They discuss how EV-pembro has reshaped treatment expectations, why unexpected complete or near-complete responses are prompting tumor board debates about cystectomy, and how careful multidisciplinary decision-making guides which patients may be considered for surgery.
Be part of the conversation. Put your sponsored messaging on this episode. Learn how.
BackTable, LLC (Producer). (2026, February 17). Ep. 290 – Urothelial Carcinoma: Consolidative Surgery & Treatment Approaches [Audio podcast]. Retrieved from https://www.backtable.com
Stay Up To Date
Follow:
Subscribe:
Sign Up:
Podcast Contributors
Synopsis
The conversation reviews early outcomes showing high rates of pathologic downstaging and the possibility that many patients may avoid additional systemic therapy after surgery, while emphasizing this approach is not yet standard of care. Dr. Khanna highlights coordination with medical oncology, radiology, and pathology, postoperative considerations, and the potential future role of biomarkers such as ctDNA. Ultimately, the episode underscores the need for clinical trials and thoughtful patient selection as clinicians navigate integrating surgery into an evolving systemic therapy landscape.
Timestamps
00:00 - Introduction
02:19 - The Evolution of Urothelial Carcinoma Treatment
05:23 - Rationale for Consolidative Surgery
12:32 - Patient Selection Criteria
15:23 - Surgical Approach and Considerations
23:58 - Pathologic Findings
31:34 - The Role of Radiation
39:38 - Biomarkers
44:10 - Prospective Trials and Future Directions
53:06 - Guidance for Urologists
Resources
Consolidative Surgery for Advanced Urothelial Carcinoma Following Induction Enfortumab Vedotin and/or Immune Checkpoint Inhibitor Therapy: A Multicenter Analysis
https://pubmed.ncbi.nlm.nih.gov/40425390/
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
https://www.nejm.org/doi/full/10.1056/NEJMoa2312117
Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer
https://www.nejm.org/doi/abs/10.1056/NEJMoa2401497
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.
Up Next
Articles
Topics
